Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sagimet Biosciences Inc. - Series A Common Stock
(NQ:
SGMT
)
5.280
+0.060 (+1.15%)
Streaming Delayed Price
Updated: 1:30 PM EDT, Apr 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sagimet Biosciences Inc. - Series A Common Stock
< Previous
1
2
3
4
5
Next >
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
June 09, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
These stocks are moving in today's pre-market session
↗
June 04, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via
Chartmill
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
↗
June 04, 2025
Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
June 04, 2025
Via
Benzinga
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
June 04, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
May 22, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 08, 2025
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
April 23, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
The market is filled with gapping stocks in Monday's session.
↗
April 21, 2025
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
March 12, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
March 11, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
February 19, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
January 27, 2025
Via
Benzinga
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
January 06, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 16, 2024
Via
Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
↗
December 16, 2024
Via
Benzinga
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
November 18, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 14, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
November 12, 2024
Via
Benzinga
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
November 07, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
↗
November 01, 2024
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.
Via
Investor's Business Daily
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
October 29, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
October 16, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
October 11, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 01, 2024
Via
Benzinga
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
October 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
September 12, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
